DrugBiological
Conatumumab clinical trials
Also written AMG 655.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
9 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2011 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Amgen (5) · NantCell, Inc. (3) · TetraLogic Pharmaceuticals (1) · Radiation Therapy Oncology Group (1)
Often tested with
Tested in the same studies.
Ganitumab (4) · Birinapant (1) · Panitumumab (1) · Capecitabine (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses conatumumab is read from its arms, and is right about nine times in ten.
Testing it · 10
- QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic CancerCompletedPhase 1/2NantCell, Inc.NCT00630552Written as AMG 655
- QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid TumorsTerminatedPhase 1/2NantCell, Inc.NCT00819169Written as AMG 655
- Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)CompletedPhase 2AmgenNCT01327612Written as Conatumumab
- QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal CarcinomaCompletedPhase 2NantCell, Inc.NCT00813605Written as AMG 655
- A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung CancerCompletedPhase 1/2AmgenNCT00534027Written as AMG 655
- Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian CancerCompletedPhase 1TetraLogic PharmaceuticalsNCT01940172Written as Conatumumab
- Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue SarcomaCompletedPhase 1/2AmgenNCT00626704Written as AMG 655
- Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal CancerCompletedPhase 1/2AmgenNCT00625651Written as AMG 655
- Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer StudyCompletedPhase 1/2AmgenNCT00630786Written as Conatumumab
- Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic CancerWithdrawnPhase 1/2Radiation Therapy Oncology GroupNCT01017822Written as conatumumab
Given in every arm · 1 — conatumumab is usual care beside what is tested
Codes
What other systems call conatumumab · ClinicalTrials.gg INT005753
- MeSH (NLM) C554537conatumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1P48L61KM0CONATUMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q3685951conatumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71015ConatumumabOne source FDA
- DrugBank DB11646One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C554537 | conatumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1P48L61KM0 | CONATUMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3685951 | conatumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71015 | Conatumumab | One source FDA |
| DrugBank | DB11646 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.